Insider Selling: USANA Health Sciences, Inc. (NYSE:USNA) Director Sells 500 Shares of Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director John Turman Fleming sold 500 shares of USANA Health Sciences stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $33.30, for a total transaction of $16,650.00. Following the sale, the director now owns 4,026 shares of the company’s stock, valued at $134,065.80. The trade was a 11.05 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

USANA Health Sciences Stock Performance

USANA Health Sciences stock traded down $0.62 during midday trading on Wednesday, hitting $32.49. 189,849 shares of the company’s stock were exchanged, compared to its average volume of 176,090. The company has a market cap of $619.32 million, a PE ratio of 11.48, a P/E/G ratio of 0.93 and a beta of 0.98. The firm has a 50-day moving average of $32.86 and a two-hundred day moving average of $36.08. USANA Health Sciences, Inc. has a 12 month low of $27.71 and a 12 month high of $50.32.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.15. The firm had revenue of $213.61 million during the quarter, compared to analysts’ expectations of $208.82 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. As a group, equities analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Institutional Trading of USANA Health Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of USNA. R Squared Ltd purchased a new stake in shares of USANA Health Sciences during the 4th quarter worth $28,000. Safe Harbor Fiduciary LLC bought a new position in USANA Health Sciences in the third quarter worth about $30,000. KBC Group NV lifted its position in shares of USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after buying an additional 519 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of USANA Health Sciences in the 4th quarter valued at about $83,000. Finally, Quantbot Technologies LP bought a new stake in shares of USANA Health Sciences in the 4th quarter valued at about $132,000. Institutional investors own 54.25% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th. Sidoti downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th. Finally, DA Davidson decreased their target price on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, February 27th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.